Where to buy Methoxphenidine for sale online

The surge in the popularity of research chemicals has led to a proliferation of sellers offering substances like Methoxphenidine. While research chemicals serve legitimate scientific purposes, evaluating the vendors’ reliability and ethics is paramount.

Sellers: When considering where to buy Methoxphenidine or any research chemical, the credibility and trustworthiness of the seller should be the primary concern. The marketplace is rife with vendors of varying repute, making extensive research a prerequisite before purchasing. Buyers must prioritize vendors with a proven track record, transparent business practices, and positive customer feedback.

Designer Drug Status: Methoxphenidine falls into the category of designer drugs, synthesized to mimic the effects of known substances while evading legal restrictions. This classification underscores the need for caution. The lack of comprehensive research into these chemicals’ safety and long-term impact means they pose an inherent risk for those seeking to experiment.

Online Availability: The ease of access to Methoxphenidine and similar research chemicals online offers benefits and drawbacks. While online accessibility can benefit researchers, it also attracts unscrupulous sellers prioritizing profit over safety and ethical considerations.

For Sale: The phrase “for sale” often serves as a marketing lure to attract buyers. Such listings should be met with skepticism. Legitimate research chemical vendors adhere to strict regulations and guidelines, emphasizing scientific research over commercial sales.

Methoxphenidine Vendors:

NameMinimal order Shipping fromDelivery by Payment method Reviews Guarantees 
Lab-Generation.com100gAsiaDHL,FedEx, UPSBank Transfer, WU, MGExistNo  
Hotchemicals.nl10gEuropeTNT,DHL,FedExBank Transfer, BitoinYes
Rcmoonlight.netAsiaTNT,DHL,FedExBank Transfer, WU, BitcoinExistYes
Research-chemical.com100gAsia, USEMS,TNT,DHL,FedEx,UPSCryptoExistYes


Methoxphenidine, also known as methoxydiphenidine, 2-MeO-Diphenidine, or MXP, belongs to the diarylethylamine class and has gained notoriety as a designer drug sold online. Its initial appearance dates back to a 1989 patent, where it was explored as a potential treatment for neurotoxic injury. Following the 2013 UK prohibition on arylcyclohexylamines, methoxphenidine and its counterpart diphenidine surfaced in the gray market, circulating in various forms like powders and tablets.
Although diphenidine exhibits a stronger affinity for the NMDA receptor, anecdotal accounts suggest that methoxphenidine possesses greater oral potency. In terms of isomeric anisyl-substituents, methoxphenidine’s affinity for the NMDA receptor falls between that of 4-MeO-Diphenidine and 3-MeO-Diphenidine, forming a structure-activity relationship consistent with other arylcyclohexylamines.

IUPAC name
CAS Number127529-46-8 
PubChem CID67833251
Chemical and physical data
Molar mass295.426 g·mol−1

Side effects

Instances of acute methoxphenidine intoxication have been documented to result in symptoms such as confusion, elevated blood pressure, and rapid heartbeat. These effects were notably responsive to treatment involving intravenous lorazepam. It’s important to note that methoxphenidine has been linked to three documented fatalities and a case involving impaired driving.
Additionally, there have been reported incidents of psychotic episodes associated with methoxphenidine, including a tragic murder case in June 2014.

Legal status

In October 2015, MXP was classified as a controlled substance in China, subject to regulatory restrictions.
Sweden also banned MXP, rendering it illegal within its borders.
In Canada, MT-45 and its analogs, including DPD within its structural group, were categorized as Schedule I controlled substances. This classification entails strict legal penalties, with maximum sentences of up to seven years for unauthorized possession. Furthermore, Health Canada took measures in May 2016 to explicitly designate DPD as a restricted drug. Occupancy is limited to law enforcement agencies, individuals holding an exemption permit, or institutions authorized by the Minister of Health.


1. What is Methoxphenidine? Methoxphenidine, often abbreviated as MXP, is a chemical compound in the diarylethylamine class. It has gained attention as a dissociative designer drug.

2. Is Methoxphenidine legal? The legal status of Methoxphenidine varies by country and jurisdiction. It’s essential to check local laws and regulations before purchasing or possessing this substance.

3. How is Methoxphenidine used? Methoxphenidine is typically ingested orally, although other methods may be attempted. It is commonly sold in powder or tablet form.

4. What are the effects of Methoxphenidine? Methoxphenidine is known for its dissociative properties, which can lead to altered perceptions, changes in consciousness, and sometimes hallucinations. Results can vary among individuals and depend on dosage and personal tolerance.

5. Is Methoxphenidine safe? The safety of Methoxphenidine is a matter of concern, as limited research has been conducted on its potential risks and long-term effects. It should be used cautiously and responsibly.

6. What are the risks associated with Methoxphenidine use? Risks of Methoxphenidine use may include confusion, elevated blood pressure, rapid heart rate, and even severe adverse reactions. Fatalities and cases of impaired driving have also been linked to its use.

7. Can Methoxphenidine be addictive? The addictive potential of Methoxphenidine is not well understood, but like other psychoactive substances, it may have the potential for psychological dependence in some individuals.

8. Where can I find more information about Methoxphenidine? Seek reliable information from credible sources such as scientific literature, government health agencies, and harm reduction organizations. It’s advisable to consult with healthcare professionals or toxicologists if you have specific questions or concerns about Methoxphenidine. Always prioritize safety and responsible use.


  1. Morris H, Wallach J (July–August 2014). “A Comprehensive Review of Dissociative Drugs: From PCP to MXE.” This enlightening review delves into the non-medical use of dissociative drugs, including Methoxphenidine. It explores their history, effects, and implications. Link
  2. Van Hout MC, Hearne E (January–March 2015). “Word of Mouse: Indigenous Harm Reduction and Online Consumerism of Methoxphenidine.” This research paper explores indigenous harm reduction strategies and the online presence of Methoxphenidine. Link
  3. Nancy M. Gray; Brian K. Cheng. “Patent EP 0346791 B1 – 1,2-diarylethylamines for treatment of neurotoxic injury”. Discover the patent detailing the potential therapeutic use of 1,2-diarylethylamines like Methoxphenidine. Link
  4. McLaughlin G, Morris N, Kavanagh PV, Power JD, O’Brien J, Talbot B, et al. (January 2016). “Test Purchase, Synthesis, and Characterization of Methoxphenidine (MXP).” This study delves into the synthesis and differentiation of Methoxphenidine and its isomers. Link
  5. Sahai MA, Davidson C, Dutta N, Opacka-Juffry J (April 2018). “Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS).” Explore the mechanisms behind the stimulant properties of psychoactive substances, including Methoxphenidine. Link
  6. Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, et al. (June 2016). “Pharmacological Investigations of Dissociative ‘Legal Highs.'” This research investigates the pharmacology of dissociative substances like Methoxphenidine. Link
  7. Hofer KE, Degrandi C, Müller DM, Zürrer-Härdi U, Wahl S, Rauber-Lüthy C, Ceschi A (December 2014). “Acute Toxicity Associated with Methoxphenidine”. Learn about the acute toxicity related to recreational Methoxphenidine use. Link
  8. Helander A, Beck O, Bäckberg M (June 2015). “Intoxications by the Dissociative New Psychoactive Substances Diphenidine and Methoxphenidine.” Explore intoxications caused by dissociative substances, including Methoxphenidine. Link
  9. Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV (May 2015). “First Reported Fatalities Associated with Methoxphenidine”. Discover the first reported fatalities linked to Methoxphenidine use. Link
  10. Stachel N, Jacobsen-Bauer A, Skopp G (March 2016). “A Methoxphenidine-Impaired Driver.” Read about an impaired driver under the influence of Methoxphenidine. Link
  11. “Man who killed mother believing her to be a witch sentenced to a minimum of five years in jail.” BBC News (17 June 2016). Learn about a criminal case involving Methoxphenidine. Link
  12. “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (in Chinese). China Food and Drug Administration (27 September 2015). Understand the regulatory status of Methoxphenidine in China. Link
  13. “Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara” (in Swedish). Folkhälsomyndigheten (24 March 2015). Learn about efforts to classify substances like Methoxphenidine as narcotics in Sweden. Link
  14. Arsenault D (1 June 2016). “Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45, and W-18)”. Canada Gazette (150, 11). Explore regulatory changes in Canada that impact substances like Methoxphenidine. Link